1.
1
Raskin P
, Rappaport EB
, Cole ST
, et al.
Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes
.
Diabetologia
. 2000;43:278–284
.
CrossRef
2.
2
Parulkar AA
, Pendergrass ML
, Granda-Ayala R
, et al.
Non-hypoglycemic effects of thiazolidinediones
.
Ann Intern Med
. 2001;134:61–71
.
MEDLINE
3.
3
Duan SZ
, Usher MG
, Mortensen RM
.
Peroxisome prolifer-ator-activated receptor-gamma-mediated effects in the vasculature
.
Circ Res
. 2008;102:283–294
.
CrossRef
4.
4
Tseng CH
, Huang TS
.
Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese type 2 diabetic patients
.
Diabetes Res Clin Pract
. 2005;70:193–194
.
Full Text |
Full-Text PDF (59 KB)
|
CrossRef
5.
5
Haffner SM
, Greenberg AS
, Weston WM
, et al.
Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes melli-tus
.
Circulation
. 2002;106:679–684
.
CrossRef
6.
6
Nordt TK
, Peter K
, Bode C
, et al.
Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells
.
J Clin Endocrinol Metab
. 2000;85:1563–1568
.
CrossRef
7.
7
Marx N
, Froehlich J
, Siam L
, et al.
Antidiabetic PPARγ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease
.
Arterioscler Thromb Vasc Biol
. 2003;23:283–288
.
CrossRef
8.
8
Randriamboavonjy V
, Pistrosch F
, Bölck B
, et al.
Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone
.
Circulation
. 2008;117:52–60
.
CrossRef
9.
9
Yu J
, Jin N
, Wang G
, et al.
Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease
.
Metabolism
. 2007;56:1396–1401
.
Abstract | Full Text |
Full-Text PDF (214 KB)
|
CrossRef
10.
10
Rosmarakis ES
, Falagas ME
.
Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials
.
Am Heart J
. 2007;154:144–150
.
Abstract | Full Text |
Full-Text PDF (414 KB)
|
CrossRef
11.
11
Sorrentino SA
, Bahlmann FH
, Besler C
, et al.
Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes melli-tus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone
.
Circulation
. 2007;116:163–173
.
CrossRef
12.
12
Raji A
, Seely EW
, Bekins SA
, et al.
Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients
.
Diabetes Care
. 2003;26:172–178
.
MEDLINE |
CrossRef
13.
13
Wang TD
, Chen WJ
, Lin JW
, et al.
Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome
.
Am J Cardiol
. 2004;93:362–365
.
Abstract | Full Text |
Full-Text PDF (73 KB)
|
CrossRef
14.
14
Esposito K
, Ciotola M
, Carleo D
, et al.
Effect of rosiglita-zone on endothelial function and inflammatory markers in patients with the metabolic syndrome
.
Diabetes Care
. 2006;29:1071–1076
.
MEDLINE |
CrossRef
15.
15
Chinetti G
, Fruchart JC
, Staels B
.
Peroxisome proliferators-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation
.
Inflamm Res
. 2000;49:497–505
.
MEDLINE |
CrossRef
16.
16
Inoue I
, Katayama S
, Takahashi K
, et al.
Troglitazone has a scavenging effect on reactive oxygen species
.
Biochem Biophys Res Commun
. 1997;235:113–116
.
CrossRef
17.
17
Chen Z
, Ishibashi S
, Perrey S
, et al.
Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice. Pleiotropic effects on CD36 expression and HDL
.
Arterioscler Thromb Vasc Biol
. 2001;21:372–377
.
18.
18
Li AC
, Brown KK
, Silvestre MJ
, et al.
Peroxisome proliferators-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
.
J Clin Invest
. 2000;106:523–531
.
MEDLINE |
CrossRef
19.
19
Shiomi T
, Tsutsui H
, Hayashidani S
, et al.
Pioglitazone, a peroxisome proliferators-activated receptor-γ agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction
.
Circulation
. 2002;106:3126–3132
.
CrossRef
20.
20
Willett WC
, Green A
, Stampfer MJ
, et al.
Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes
.
N Engl J Med
. 1987;317:1303–1309
.
MEDLINE |
CrossRef
21.
21
Li YH
, Chen JH
, Tsai WC
, et al.
Synergic effect of thrombomodulin promoter-33G/A polymorphism and smoking on the onset of acute myocardial infarction
.
Thromb Haemost
. 2002;87:86–91
.
MEDLINE
22.
22
Teng JK
, Lin LJ
, Tsai LM
, et al.
Acute myocardial infarction in young and very old Chinese adults: clinical and therapeutic implications
.
Int J Cardiol
. 1994;44:29–36
.
MEDLINE |
CrossRef
23.
23
Zeiher AM
, Schächinger V
, Minners J
.
Long-term cigarette smoking impairs endothelium-dependent coronary artery vasodilator function
.
Circulation
. 1995;92:1094–1100
.
MEDLINE
24.
24
Tracy RP
, Psaty BM
, Macy E
, et al.
Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects
.
Arterioscler Thromb Vasc Biol
. 1997;17:2167–2176
.
MEDLINE
25.
25
Blann AD
, Steele C
, McCollum CN
.
The influence of smoking on soluble adhesion molecules and endothelial cell markers
.
Thromb Res
. 1997;85:433–438
.
Full Text |
Full-Text PDF (818 KB)
|
CrossRef
26.
26
Sharp DS
, Benowitz NL
, Bath PM
, et al.
Cigarette smoking sensitizes and desensitizes impedance-measured ADP-induced platelet aggregation in whole blood
.
Thromb Haemost
. 1995;74:730–735
.
MEDLINE
27.
27
Nakamura T
, Ebihara I
, Shimada N
, et al.
Effect of cigarette smoking on plasma metalloproteinase-9 concentration
.
Clin Chim Acta
. 1998;276:173–177
.
MEDLINE |
CrossRef
28.
28
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
.
Executive summary of the third report of the National Cholesterol Education Program (NECP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
.
JAMA
. 2001;285:2486–2497
.
MEDLINE |
CrossRef
29.
29
Chao TH
, Tsai LM
, Tsai WC
, et al.
Effect of atrial fibrillation on pulmonary venous flow patterns assessed by Doppler transesophageal echocardiography
.
Chest
. 2000;117:1546–1550
.
MEDLINE |
CrossRef
30.
30
Matthews DR
, Hosker JP
, Rudenski AS
, et al.
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
.
Diabetologia
. 1985;28:412–419
.
CrossRef
31.
31
Hijmering ML
, Stroes ES
, Pasterkamp G
, et al.
Variability of flow mediated dilation: consequences for clinical application
.
Atherosclerosis
. 2001;157:369–373
.
Abstract | Full Text |
Full-Text PDF (86 KB)
|
CrossRef
32.
32
De Roos NM
, Bots ML
, Schouten EG
, et al.
Within-subject variability of flow-mediated vasodilation of the brachial artery in healthy men and women: implications for experimental studies
.
Ultrasound Med Biol
. 2003;29:401–406
.
Abstract | Full Text |
Full-Text PDF (83 KB)
|
CrossRef
33.
33
Malik J
, Wichterle D
, Haas T
, et al.
Repeatability of noninvasive surrogates of endothelial function
.
Am J Cardiol
. 2004;94:693–696
.
Abstract | Full Text |
Full-Text PDF (112 KB)
|
CrossRef
34.
34
McEniery CM
, Wallace S
, Mackenzie IS
, et al.
Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans
.
Hypertension
. 2006;48:602–608
.
CrossRef
35.
35
Chowienczyk PJ
, Kelly RP
, MacCallum H
, et al.
Photoplethysmographic assessment of pulse wave reflection
.
J Am Coll Cardiol
. 1999;34:2007–2014
.
Abstract | Full Text |
Full-Text PDF (353 KB)
|
CrossRef
36.
36
Hayward CS
, Kraidly M
, Webb CM
, et al.
Assessment of endothelial function using peripheral waveform analysis. A clinical application
.
J Am Coll Cardiol
. 2002;40:521–528
.
Abstract | Full Text |
Full-Text PDF (175 KB)
|
CrossRef
37.
37
Wilkinson IB
, Hall IR
, MacCallum H
, et al.
Pulse wave analysis. Clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function
.
Arterioscler Thromb Vasc Biol
. 2002;22:147–152
.
CrossRef
38.
38
Gopaul NK
, Manraj MD
, Hébé A
, et al.
Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism
.
Diabetologia
. 2001;44:706–712
.
CrossRef
39.
39
Hetzel J
, Balletshofer B
, Rittig K
, et al.
Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers
.
Arterioscler Thromb Vasc Biol
. 2005;25:1804–1809
.
CrossRef
40.
40
Dandona P
, Aljada A
.
A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis
.
Am J Cardiol
. 2002;90:G27–G33
.
41.
41
Chao TH
, Li YH
, Chen JH
, et al.
The 161TT genotype in the exon 6 of peroxisome proliferator-activated receptor γ gene is associated with premature acute myocardial infarction and increased lipid peroxidation in habitual heavy smokers
.
Clin Sci
. 2004;107:461–466
.
42.
42
Amoruso A
, Bardelli C
, Gunella G
, et al.
Quantification of PPAR-gamma protein in monocyte/macrophages from healthy smokers and non-smokers: a possible direct effect of nicotine
.
Life Sci
. 2007;81:906–915
.
CrossRef
43.
43
Selvin E
, Bolen S
, Yeh HC
, et al.
Cardiovascular outcomes in trials of oral diabetes medications: a systematic review
.
Arch Intern Med
. 2008;168:2070–2080
.
CrossRef
44.
44
Monami M
, Marchionni N
, Mannucci E
.
Winners and losers at the rosiglitazone gamble. A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone
.
Diabetes Res Clin Pract
. 2008;82:48–57
.
Abstract | Full Text |
Full-Text PDF (524 KB)
|
CrossRef